

DESCRIPTION	
<b>Species Reactivity</b>	Equine
<b>Specificity</b>	Detects equine TNF-alpha in direct ELISAs and Western blots. In Western blots, approximately 35% cross-reactivity with recombinant mouse TNF-alpha and recombinant rat TNF-alpha is observed.
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	<i>E. coli</i> -derived recombinant equine TNF-alpha Leu78-Leu234 Accession # NP_001075288
<b>Endotoxin Level</b>	<0.10 EU per 1 $\mu$ g of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 $\mu$ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 $\mu$ m filtered solution in PBS.

APPLICATIONS	
<b>Please Note:</b> Optimal dilutions should be determined by each laboratory for each application. <i>General Protocols</i> are available in the <i>Technical Information</i> section on our website.	
	<b>Recommended Concentration      Sample</b>
<b>Western Blot</b>	0.1 $\mu$ g/mL      Recombinant Equine TNF- $\alpha$ (Catalog # 1814-ET)
<b>Immunocytochemistry</b>	5-15 $\mu$ g/mL      See Below
<b>Neutralization</b>	Measured by its ability to neutralize TNF- $\alpha$ -induced cytotoxicity in the L-929 mouse fibroblast cell line. The Neutralization Dose (ND <sub>50</sub> ) is typically 0.01-0.03 $\mu$ g/mL in the presence of 1 ng/mL Recombinant Equine TNF- $\alpha$ and 1 $\mu$ g/mL actinomycin D.

DATA	
<p><b>Neutralization</b></p> <p><b>Cytotoxicity Induced by TNF-<math>\alpha</math> and Neutralization by Equine TNF-<math>\alpha</math> Antibody.</b> Recombinant Equine TNF-<math>\alpha</math> (Catalog # 1814-ET) induces cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by Resazurin (Catalog # AR002). Cytotoxicity elicited by Recombinant Equine TNF-<math>\alpha</math> (1 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Equine TNF-<math>\alpha</math> Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1814). The ND<sub>50</sub> is typically 0.01-0.03 <math>\mu</math>g/mL in the presence of the metabolic inhibitor actinomycin D (1 <math>\mu</math>g/mL).</p>	<p><b>Immunocytochemistry</b></p> <p><b>TNF-<math>\alpha</math> in Equine PBMCs.</b> TNF-<math>\alpha</math> was detected in immersion fixed equine peripheral blood mononuclear cells (PBMCs) using Goat Anti-Equine TNF-<math>\alpha</math> Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1814) at 15 <math>\mu</math>g/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for <a href="#">Fluorescent ICC Staining of Non-adherent Cells</a>.</p>

PREPARATION AND STORAGE	
<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

Tumor necrosis factor alpha (TNF- $\alpha$ ) also known as cachectin and TNFSF2, is the prototypic ligand of the TNF superfamily. It is a pleiotropic molecule that plays a central role in inflammation, apoptosis, and immune system development. TNF- $\alpha$  is produced by a wide variety of immune and epithelial cell types (1, 2). Equine TNF- $\alpha$  consists of a 35 amino acid (aa) cytoplasmic domain, a 21 aa transmembrane segment, and a 178 aa extracellular domain (ECD) (3). Within the ECD, equine TNF- $\alpha$  shares 69%-88% aa sequence identity with bovine, canine, cotton rat, feline, human, mouse, porcine, rat, and rhesus TNF- $\alpha$ . The 26 kDa type 2 transmembrane protein is assembled intracellularly to form a noncovalently linked homotrimer (4). Ligation of this complex induces reverse signaling that promotes lymphocyte costimulation but diminishes monocyte responsiveness (5). Cleavage of membrane bound TNF- $\alpha$  by TACE/ADAM17 releases a 55 kDa soluble trimeric form of TNF- $\alpha$  (6, 7). TNF- $\alpha$  trimers bind the ubiquitous TNF RI and the hematopoietic cell-restricted TNF RII, both of which are also expressed as homotrimers (1, 8). TNF- $\alpha$  regulates lymphoid tissue development through control of apoptosis (2). It also promotes inflammatory responses by inducing the activation of vascular endothelial cells and macrophages (2). TNF- $\alpha$  is a key cytokine in the development of several inflammatory disorders (9). It contributes to the development of type 2 diabetes through its effects on insulin resistance and fatty acid metabolism (10, 11).

**References:**

1. Idriss, H.T. and J.H. Naismith (2000) *Microsc. Res. Tech.* **50**:184.
2. Hehlgans, T. and K. Pfeffer (2005) *Immunology* **115**:1.
3. Su, X.Z. *et al.* (1991) *Gene* **107**:319.
4. Tang, P. *et al.* (1996) *Biochemistry* **35**:8216.
5. Eissner G. *et al.* (2004) *Cytokine Growth Factor Rev.* **15**:353.
6. Black, R.A. *et al.* (1997) *Nature* **385**:729.
7. Moss, M.L. *et al.* (1997) *Nature* **385**:733.
8. Loetscher, H. *et al.* (1991) *J. Biol. Chem.* **266**:18324.
9. Clark, I.A. (2007) *Cytokine Growth Factor Rev.* **18**:335.
10. Romanatto, T. *et al.* (2007) *Peptides* **28**:1050.
11. Hector, J. *et al.* (2007) *Horm. Metab. Res.* **39**:250.